ARTICLE | Company News
Compugen deal
November 9, 2009 8:00 AM UTC
Compugen granted an undisclosed diagnostic company exclusive, worldwide rights to its CGEN-226 biomarker to develop and commercialize a diagnostic for the early detection of preeclampsia. CGEN-226 is ...